RSK2 protects mice against TNF-induced bone loss

Area of Science:

• Bone biology
• Inflammation
• Molecular signaling

Background:

• Tumor necrosis factor-alpha (TNF-α) is a critical cytokine involved in regulating bone metabolism and mediating inflammatory bone loss.
• The precise molecular signaling pathways downstream of TNF-α that control bone loss remain incompletely understood.

Purpose of the Study:

• To investigate the role of ribosomal S6 kinase 2 (RSK2) in the molecular mechanisms of TNF-α-induced bone loss.
• To elucidate how RSK2 inactivation impacts bone formation and resorption in the context of TNF-α overexpression.

Main Methods:

• Utilized human TNF transgenic (hTNFtg) mice model with inactivated RSK2.
• Analyzed bone phenotypes, including bone formation and osteoclast activity.
• Assessed TNF-α-induced apoptosis and osteoclast supportive activity in osteoblasts and osteocytes.

Main Results:

• Inactivation of RSK2 significantly accelerated and amplified systemic bone loss in hTNFtg mice.
• Observed a decrease in bone formation due to reduced osteoblast numbers.
• Documented a substantial increase in bone destruction mediated by osteoclasts.
• Demonstrated increased sensitivity of osteoblasts and osteocytes to TNF-induced apoptosis and enhanced osteoclast supportive function.

Conclusions:

• RSK2 acts as a crucial negative regulator of TNF-α-induced bone loss.
• RSK2 deficiency exacerbates bone loss through increased osteoblast/osteocyte apoptosis and enhanced osteoclastogenesis.
• Targeting RSK2 may offer a therapeutic strategy for inflammatory bone diseases.